Furthermore, semaglutide prevents MASLD/MASH-driven HCC progression in metabolic preclinical models, partly by correcting adipokine imbalances (low adiponectin, high leptin) associated with insulin resistance, which removes a key chronic inflammatory and pro-oncogenic signal linked to the disease (Kojima et al., 2020)
*Correspondence: Trinidad Montero-Melendez, [email protected] These authors share first authorship This article was submitted to Inflammation, a section of the journal Frontiers in Immunology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
The gut and brain communicate bidirectionally through the vagus nerve, immune signaling, and metabolic pathways
Side effects like nausea, reduced appetite, and mild gastrointestinal discomfort are most common during this period and at each subsequent dose increase
Clinical evidence indicates that injectable options can help patients lose 15% to 20% of their total body weight over a sustained period, while oral forms typically yield a more modest 5% to 10% reduction
doi: 10.1016/j.cmet.2021.12.021 74 LargerEAlbrechtsen WewerNJHansenLHGellingRWCapeauJDeaconCFet al